Home World News Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain... World News Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 402 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients... September 28, 2026 Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests May 23, 2018 FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab... August 5, 2026 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 Load more HOT NEWS Fatiga relacionada con el cáncer: Lo que las personas con cáncer... Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in... Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone... New on NCI’s Websites for August 2024
